At a glance
ClinicalIndex Comparison RecordN/ACompleted· 44 enrolled
Drug / intervention
Elio +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Protein Hydrolysate Supplementation to Influence the Expression of Strength Recovery and Systemic Muscle Function Markers Following Resistance Type Exercise in Male Subjects.
In Brief
A clinical study evaluating Elio and SMCC for Muscle Injury. Completed, enrolled 44 participants across 1 site.
Detailed Summary
A randomised placebo controlled, double-blind, 30 Volunteer trial of Elio™ administered 2.4 grams per day in assessing its effects on post-exercise strength recovery and increases in markers associated with muscle injury and exertion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMuscle Injury
CountriesIreland
CollaboratorsSports Surgery Clinic, Santry, Dublin
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartAug 2021
First PostedDec 2021
Primary CompletionJan 2022
Study CompletionApr 2022
TodayJul 2026
First PostedDec 16, 2021
Enrollment StartAug 6, 2021
Primary CompletionJan 22, 2022
Study CompletionApr 4, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.5 years ago
Interventions
Eliodietary
Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract
SMCCother
Placebo comparator